Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04524455 · ClinicalTrials.gov registry record · Phase 1
Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT04524455 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 17 participants.
The verdict
NCT04524455, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusion (cIV) blinatumomab.
Interventions
- DRUG Blinatumomab
- DRUG AMG 404
- DRUG Dexamethasone Premedication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2020-10-02 |
| Est. Completion | 2023-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04524455
The ClinicalTrials.gov registry entry for NCT04524455 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blinatumomab is the first listed.
NCT04524455 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04524455 about?
NCT04524455 is a clinical study titled "Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL". The primary objective of this phase 1b study is to evaluate the safety and tolerability of blinatumomab and AMG 404 in combination in adults with R/R B-ALL and to estimate the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of AMG 404 when combined with continuous intravenous infusi...
What is the current status of trial NCT04524455?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2020-10-02. Estimated completion is 2023-01-24.
What interventions are being tested in trial NCT04524455?
The interventions under investigation include: Blinatumomab (DRUG), AMG 404 (DRUG), Dexamethasone Premedication (DRUG).
Who is sponsoring clinical trial NCT04524455?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.